Jeong Myung-Hwa, Kim Hyungjoo, Kim Tae-Hun, Kim Moon-Hong, Kim Beob-Jong, Ryu Sang-Young
Department of Obstetrics and Gynecology, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
Obstet Gynecol Sci. 2019 Jan;62(1):35-45. doi: 10.5468/ogs.2019.62.1.35. Epub 2018 Dec 3.
This study aimed to evaluate the prognostic impact of age at diagnosis, and pretreatment hematologic markers, including lymphocyte percentage and the neutrophil-to-lymphocyte ratio (NLR), in patients with locally advanced cervical cancer (LACC) treated with definitive radiotherapy (RT).
A total of 392 patients with LACC (stage IIb to IVa) treated with cisplatin-based concurrent chemoradiotherapy or RT alone between 2001 and 2012 were retrospectively enrolled. Clinical data and pretreatment complete blood counts were extracted from electronic medical records of the patients, and analyzed. Treatment outcomes, progression-free survival (PFS), and overall survival (OS) were evaluated.
Low lymphocyte percentage and a high NLR were associated with younger age, advanced stage, larger tumor size, lymph nodes metastasis, and treatment failure. The cut-off value for lymphocyte percentage and NLR was determined using a receiver operating characteristic curve. In univariate analysis, low lymphocyte percentage (≤24%) was associated with poor PFS and OS, while high NLR (>2.8) was significantly associated only with PFS. In multivariate analysis, both lymphocyte percentage (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.40-0.85; =0.005) and NLR (HR, 1.55; 95% CI, 1.07-2.25; =0.022) had independent prognostic value for PFS. Compared to younger patients (age ≤50 years), older patients (age >60 years) had a lower risk of death.
Although the lymphocyte percentage did not remain significant in multivariate analysis for OS, it was predictive of PFS and OS. Thus, lymphocyte percentage is a simple hematologic parameter with a significant prognostic value in patients with LACC treated with definitive RT.
本研究旨在评估确诊时年龄以及包括淋巴细胞百分比和中性粒细胞与淋巴细胞比值(NLR)在内的治疗前血液学标志物对接受根治性放疗(RT)的局部晚期宫颈癌(LACC)患者预后的影响。
回顾性纳入2001年至2012年间共392例接受以顺铂为基础的同步放化疗或单纯放疗的LACC患者(IIb至IVa期)。从患者的电子病历中提取临床数据和治疗前全血细胞计数并进行分析。评估治疗结果、无进展生存期(PFS)和总生存期(OS)。
淋巴细胞百分比低和NLR高与年龄较小、分期较晚、肿瘤体积较大、淋巴结转移及治疗失败相关。使用受试者工作特征曲线确定淋巴细胞百分比和NLR的临界值。单因素分析中,淋巴细胞百分比低(≤24%)与PFS和OS较差相关,而NLR高(>2.8)仅与PFS显著相关。多因素分析中,淋巴细胞百分比(风险比[HR],0.59;95%置信区间[CI],0.40 - 0.85;P = 0.005)和NLR(HR,1.55;95% CI,1.07 - 2.25;P = 0.022)对PFS均具有独立预后价值。与年轻患者(年龄≤50岁)相比,老年患者(年龄>60岁)死亡风险较低。
尽管淋巴细胞百分比在OS的多因素分析中未保持显著意义,但它可预测PFS和OS。因此,淋巴细胞百分比是接受根治性放疗的LACC患者中具有显著预后价值的简单血液学参数。